Barcelona, Spain
Biotechnology
inbiomotion.com
Inbiomotion is a Barcelona-based personalized medicine company incorporated in 2010 with the goal of Developing biomarkers predict bone metastasis That to Improve the quality of life of cancer patients. The company is a spin out of the IRB Barcelona and ICREA Research Institutions and was founded by Dr. Roger Gomis.
Our Activities are focused on the development of a diagnostic assay based on a selective single gene / protein biomarker That Predicts Those patients at risk of suffering bone-specific metastases from primary tumors. The exquisite selectivity of our lead biomarker Provides the grounds for the development of companion diagnostics – Selecting That Will patients benefit from the preventive use of anti-metastatic bone drugs, and making a step forward in the clinical standard of care using personalized medicine.
Roger R. Gomis (PhD.) is the Non-Executive Director & Founder & Acting CSO at Inbiomotion.
Roger is a group leader of the Oncology Program at the Institute for Research in Biomedicine, Barcelona. Roger developed his professional career primarily in the field of breast cancer metastasis.
He holds Bachelor Degrees in Biochemistry and in Business.
Roger received his Ph.D. Degree in Biochemistry from the University of Barcelona in 2002.
He was a postdoctoral fellow at Memorial Sloan-Kettering Cancer Center in Prof. Joan Massagus laboratory.
Laia is responsible for identifying and evaluating investment opportunities from the scientific and business perspectives.
Laia is a board observer at AM-Pharma and serves on the board of Inbiomotion.
Prior to joining Ysios, she assessed commercial and scientific licensing-in opportunities as part of the European New Business Development team at Janssen-Cilag, a pharmaceutical company of the Johnson & Johnson group.
Laia previously worked at the biotechnology cluster of Cambridge, UK, in companies such as Spirogen, Medivir and UCB-Celltech. Her activities ranged from establishing a combinatorial chemistry platform, designing and preparing enzyme inhibitors, planning and budgeting large scale processes at the laboratory level, and outsourcing newly developed technology to contract research organizations.
Jol oversees all operations at Ysios Capital, including management, strategy and standard operations.
Jol serves on the board of TiGenix, AM-Pharma, MedLumics, and is chairman of the board at Inbiomotion. Formerly, he was board observer at Biovex (now AMGEN) and chairman of the board at Cellerix (now TiGenix).
Previously, Jol co-founded GLYCART Biotechnology AG (Zrich, Switzerland) in March 2001 and was Chief Executive since inception. He raised 15 million in three rounds of financing for GLYCART before the company was sold to F.Hoffmann-La Roche Ltd in July 2005, a deal lauded as the deal of the year by the European Venture Capital magazine. As Chief Executive, he led all the fund-raising efforts, established a pan-European investment syndicate with leading venture capital firms and structured, negotiated and executed several key in- and out-licensing agreements with global pharmaceutical and biotechnology companies.
Jon Askaa (PhD.) is the Non-Executive Director (Independent) at Inbiomotion.
Jon is currently Chief Medical Officer of Medical Prognosis (Denmark).
He was previously Director of Companion Diagnostics at Genentech Inc where he was responsible for development and implementation of Companion Diagnostic assays for Genentechs targeted therapy programs.
Before that, he worked at Dako in Denmark and in California and was responsible for the development and launching of the HercepTest and several other Companion Diagnostic assays.
Juan Carlos Tercero (PhD.) is the Head of Product Development at Inbiomotion.
Juan Carlos is Head of Product Development at Inbiomotion.
He was previously Head of Molecular Medicine of PharmaMar (Zeltia Group) for eight years where he was responsible of Pharmacogenomics and Translational Research projects focused on the elucidation of mechanism of action and the identification of biomarkers of drug response for clinical development of anti-cancer compounds.
Previously he was,
Director of the Pharmacogenomics Laboratory,
Technical Director of PharmaGen (Madrid, Spain) providing DNA fingerprinting services and developing molecular diagnostic kits for detection of tumor markers and infectious diseases using PCR techniques.
Before that, he spent 3 years of post-doctoral training in basic biomedical research at the National Institutes of Health (USA).
Juan Carlos holds a PhD in Biology from the U. Complutense de Madrid.
David L. Lacey (MD.) is the Non-Executive Director (Independent) at Inbiomotion.
David received both his undergraduate and medical degrees from the University of Colorado and his accomplishments were recognized by his nomination to Phi Beta Kappa and Alpha Omega Alpha, respectively.
To pursue his research interest in bone biology in conjunction with completing his post graduate medical education, he continued his training at Washington University, St. Louis, Missouri.
He moved from academia to an industry setting when he joined Amgen. During the last five years of his tenure he assumed the head of Discovery Research (> 1200 FTEs) for Amgen. In this capacity, he charted the course and motivated a diverse senior team of scientific leaders from different disciplines as well as engaging and managing a diverse stakeholder network.